Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Clin Respir J ; 12(9): 2441-2445, 2018 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-30015374

RESUMEN

BACKGROUND/AIMS: The tracheal bronchus is a rare congenital abnormality with incidence reported in a range of 0.1%-2%. Infrequently, malignancy has been reported as occurring in the tracheal bronchus. In order to ascertain a relationship between malignancy and the tracheal bronchus, we performed a literature review and present a case series. METHODS: We reviewed 21 case reports of malignancy occurring in the tracheal bronchus. CONCLUSION: Although the number of cases is limited, it appears that bronchoscopy is the most frequently utilized diagnostic tool. Surgery portends the best clinical results even in higher stages of malignancy. Squamous cell carcinoma is the most common type of malignancy to occur in the tracheal bronchus.


Asunto(s)
Bronquios/anomalías , Broncoscopía/métodos , Carcinoma de Células Escamosas/cirugía , Tráquea/anomalías , Bronquios/patología , Broncoscopía/normas , Carcinoma de Células Escamosas/tratamiento farmacológico , Carcinoma de Células Escamosas/patología , Niño , Humanos , Neoplasias Pulmonares/tratamiento farmacológico , Neoplasias Pulmonares/patología , Neoplasias Pulmonares/cirugía , Masculino , Estudios Retrospectivos , Análisis de Supervivencia , Tráquea/patología
2.
PLoS One ; 7(6): e39809, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22768130

RESUMEN

BACKGROUND: Mucus stasis in chronic obstructive pulmonary disease (COPD) is a significant contributor to morbidity and mortality. Potentiators of cystic fibrosis transmembrane conductance regulator (CFTR) activity pharmacologically enhance CFTR function; ivacaftor is one such agent approved to treat CF patients with the G551D-CFTR gating mutation. CFTR potentiators may also be useful for other diseases of mucus stasis, including COPD. METHODS AND FINDINGS: In primary human bronchial epithelial cells, exposure to cigarette smoke extract diminished CFTR-mediated anion transport (65.8±0.2% of control, P<0.005) and mucociliary transport (0.17±0.05 µm/sec vs. 2.4±0.47 µm/sec control, P<0.05) by reducing airway surface liquid depth (7.3±0.6 µm vs. 13.0±0.6 µm control, P<0.005) and augmenting mucus expression (by 64%, P<0.05) without altering transepithelial resistance. Smokers with or without COPD had reduced CFTR activity measured by nasal potential difference compared to age-matched non-smokers (-6.3±1.4 and -8.0±2.0 mV, respectively vs. -15.2±2.7 mV control, each P<0.005, n = 12-14/group); this CFTR decrement was associated with symptoms of chronic bronchitis as measured by the Breathlessness Cough and Sputum Score (r = 0.30, P<0.05) despite controlling for smoking (r = 0.31, P<0.05). Ivacaftor activated CFTR-dependent chloride transport in non-CF epithelia and ameliorated the functional CFTR defect induced by smoke to 185±36% of non-CF control (P<0.05), thereby increasing airway surface liquid (from 7.3±0.6 µm to 10.1±0.4 µm, P<0.005) and mucociliary transport (from 0.27±0.11 µm/s to 2.7±0.28 µm/s, P<0.005). CONCLUSIONS: Cigarette smoking reduces CFTR activity and is causally related to reduced mucus transport in smokers due to inhibition of CFTR dependent fluid transport. These effects are reversible by the CFTR potentiator ivacaftor, representing a potential therapeutic strategy to augment mucociliary clearance in patients with smoking related lung disease.


Asunto(s)
Aminofenoles/farmacología , Regulador de Conductancia de Transmembrana de Fibrosis Quística/metabolismo , Enfermedades Pulmonares/fisiopatología , Quinolonas/farmacología , Fumar/fisiopatología , Adulto , Anciano , Anciano de 80 o más Años , Demografía , Células Epiteliales/efectos de los fármacos , Células Epiteliales/metabolismo , Células Epiteliales/patología , Femenino , Humanos , Transporte Iónico/efectos de los fármacos , Enfermedades Pulmonares/metabolismo , Masculino , Potenciales de la Membrana/efectos de los fármacos , Persona de Mediana Edad , Moco/efectos de los fármacos , Moco/metabolismo , Fumar/metabolismo
3.
Chest ; 138(4): 919-28, 2010 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-20472865

RESUMEN

BACKGROUND: The transepithelial nasal potential difference (NPD) is used to assess cystic fibrosis transmembrane conductance regulator (CFTR) activity. Unreliability, excessive artifacts, and lack of standardization of current testing systems can compromise its use as a diagnostic test and outcome measure for clinical trials. METHODS: To determine whether a nonperfusing (agar gel) nasal catheter for NPD measurement is more reliable and less susceptible to artifacts than a continuously perfusing nasal catheter, we performed a multicenter, randomized, crossover trial comparing a standardized NPD protocol using an agar nasal catheter with the same protocol using a continuously perfusing catheter. The data capture technique was identical in both protocols. A total of 26 normal adult subjects underwent NPD testing at six different centers. RESULTS: Artifact frequency was reduced by 75% (P < .001), and duration was less pronounced using the agar catheter. The measurement of sodium conductance was similar between the two catheter methods, but the agar catheter demonstrated significantly greater CFTR-dependent hyperpolarization, because Δ zero Cl- + isoproterenol measurements were significantly more hyperpolarized with the agar catheter (224.2 ± 12.9 mV with agar vs 18.2 ± 9.1 mV with perfusion, P < .05). CONCLUSIONS: The agar nasal catheter approach demonstrates superior reliability compared with the perfusion nasal catheter method for measurement of NPD. This nonperfusion catheter method should be considered for adoption as a standardized protocol to monitor CFTR activity in clinical trials.


Asunto(s)
Cateterismo/métodos , Regulador de Conductancia de Transmembrana de Fibrosis Quística/fisiología , Fibrosis Quística/fisiopatología , Potenciales de la Membrana/fisiología , Mucosa Nasal/fisiología , Adulto , Agar , Análisis de Varianza , Artefactos , Estudios Cruzados , Femenino , Geles , Humanos , Masculino
4.
AMIA Annu Symp Proc ; : 61-5, 2003.
Artículo en Inglés | MEDLINE | ID: mdl-14728134

RESUMEN

Primary Care Office InSite (PCOI) is a Web-based intranet application that provides ready access to a collection of information useful in primary care. The PCOI Web site was developed by, and is widely used within, the Massachusetts General Hospital (MGH) and its affiliated community practices. Over 1600 users logged 60,000 separate sessions in the past year. The site contains clinical practice guidelines, patient educational material, drug prescription and cost information and referral information, all designed for use during routine patient care activity. This paper discusses the problems encountered and the lessons learned during an ongoing experiment to disseminate PCOI via the Internet to four distant and very different ambulatory care sites. None of these sites (a rural community hospital, a city-wide health care network, an inner-city general hospital, and an Indian Health Service hospital have the resources to develop such an application internally.


Asunto(s)
Sistemas de Información en Atención Ambulatoria , Sistemas de Apoyo a Decisiones Clínicas/organización & administración , Atención Primaria de Salud , Actitud hacia los Computadores , Redes de Comunicación de Computadores , Humanos , Servicios de Información , Massachusetts , Innovación Organizacional , Guías de Práctica Clínica como Asunto
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...